|
Stephen M Moerlein, PhD, BCNP
Associate Professor of Radiology
|
Education
PhD, Chemistry, Washington University, St. Louis, MO 1982MA, Chemistry, Washington University, St. Louis, MO 1979
BS, Pharmacy, University of Illinois, Chicago, IL 1976
BS, Pharmacy, University of Illinois, Chicago, IL 1976
Research Involvement
Imaging techniques, such as positron emission tomography (PET),
single photon emission computerized tomography (SPECT) and y-scintigraphy offer unique
opportunities for biomedical research. Because the in vive tissue distribution of
radiotracers is reconstructed using such imaging equipment, this technique permits
the noninvasive study of physiological function (metabolism, pharmacology) rather
than anatomy alone, as is the case for MRI or CT scanning. Moreover, application of
these modalities to human subjects is possible, and repeated studies can be performed
on the same individual.
This laboratory is involved with the development, evaluation, and application of new radiopharmaceutical probes for the study of physiology and pathophysiology. Rapid synthetic techniques are applied to the production of biochemicals and biologically-active structures that contain radionuclides such as 11C, 18F or 68Ga for PET, and 111In or 123I for SPECT. New tracer structures are compared with standard compounds of known activity using in vitro techniques, such as receptor-binding assays, or ex vive biodistribution methods involving dissection. The metabolism of these tracers is an additional concern, and is examined via in vitro or in vive experiments. Promising radiopharmaceuticals are used for imaging applications in primates, and modeling of tracer kinetic behavior allows quantification of physiological processes in vive. A major goal of this research is to develop radiopharmaceuticals that have clinical utility in human subjects. Current areas of emphasis are radiotracers for examination ofneuroreceptor systems and cerebral perfusion.
This laboratory is involved with the development, evaluation, and application of new radiopharmaceutical probes for the study of physiology and pathophysiology. Rapid synthetic techniques are applied to the production of biochemicals and biologically-active structures that contain radionuclides such as 11C, 18F or 68Ga for PET, and 111In or 123I for SPECT. New tracer structures are compared with standard compounds of known activity using in vitro techniques, such as receptor-binding assays, or ex vive biodistribution methods involving dissection. The metabolism of these tracers is an additional concern, and is examined via in vitro or in vive experiments. Promising radiopharmaceuticals are used for imaging applications in primates, and modeling of tracer kinetic behavior allows quantification of physiological processes in vive. A major goal of this research is to develop radiopharmaceuticals that have clinical utility in human subjects. Current areas of emphasis are radiotracers for examination ofneuroreceptor systems and cerebral perfusion.
Selected Publications
1. Moerlein, S.M., Mintun, M.A., Perlmutter, J.S., Welch, M.J. and Siegel, B.A. USP Standards for
Flumazenil C-11 Injection. Pharm. Forum 24: 6360-6365 (1998).
2. Moerlein, S.M., Perlmutter, J.S., Markham, J. and Welch, M.J. In vivo kinetics of [F-18](N- methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding. J. Cereb. Blood Flow Metab. 17: 833-845 (1997).
3. Moerlein, S.M., Perlmutter, J.S., Cutler, P.D. and Welch, M.J. Radiation Dosimetry of [F-18](N- methyl)benperidol as detennined by whole-body PET imaging of primates. Nucl. Med. Biol. 24: 311-318(1997).
4. Perlmutter, J.S., Stambuk, M.K., Markham J., Black, K.J., McGee-Minnich, L., Jankovic, J. and Moerlein, S.M. Decreased [F-18]spiperone binding in putamen in idiopathic focal dystonia. J. Neurosci. 17: 843-859 (1997).
5. Moerlein, S.M., Perlmutter, J.S. and Welch, M.J. Specific, reversible binding of [F-18]benperidol to baboon D, receptors: PET evaluation of an improved [F18]-labeled ligand. Nucl. Med. Biol. 22: 809-815 (1995).
6. Banks, W.R., Moerlein, S.M., Parkinson, D. and Welch, M.J. Synthesis of w-nuoroallcoxy and allcoxy derivatives ofraclopride: Evaluation as radioligands for PET study of cerebral D2 receptors. Med. Chem. Res. 5: 150-173 (1994).
7. Moerlein, S.M., Perlmutter, J.S., Welch, M.J. and Raichle, M.E. First-pass extraction fraction of iodine-123 labeled perfusion tracers in living primate brain. Nucl. Med. Biol. 21: 847-855 (1993).
2. Moerlein, S.M., Perlmutter, J.S., Markham, J. and Welch, M.J. In vivo kinetics of [F-18](N- methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding. J. Cereb. Blood Flow Metab. 17: 833-845 (1997).
3. Moerlein, S.M., Perlmutter, J.S., Cutler, P.D. and Welch, M.J. Radiation Dosimetry of [F-18](N- methyl)benperidol as detennined by whole-body PET imaging of primates. Nucl. Med. Biol. 24: 311-318(1997).
4. Perlmutter, J.S., Stambuk, M.K., Markham J., Black, K.J., McGee-Minnich, L., Jankovic, J. and Moerlein, S.M. Decreased [F-18]spiperone binding in putamen in idiopathic focal dystonia. J. Neurosci. 17: 843-859 (1997).
5. Moerlein, S.M., Perlmutter, J.S. and Welch, M.J. Specific, reversible binding of [F-18]benperidol to baboon D, receptors: PET evaluation of an improved [F18]-labeled ligand. Nucl. Med. Biol. 22: 809-815 (1995).
6. Banks, W.R., Moerlein, S.M., Parkinson, D. and Welch, M.J. Synthesis of w-nuoroallcoxy and allcoxy derivatives ofraclopride: Evaluation as radioligands for PET study of cerebral D2 receptors. Med. Chem. Res. 5: 150-173 (1994).
7. Moerlein, S.M., Perlmutter, J.S., Welch, M.J. and Raichle, M.E. First-pass extraction fraction of iodine-123 labeled perfusion tracers in living primate brain. Nucl. Med. Biol. 21: 847-855 (1993).
